HAMLET Pharma initiates a GLP study to evaluate if intracerebral infusion of the drug candidate Alpha1H has any toxic effects
Hamlet Pharma is on track with its plans to engage in a clinical trial of Alpha1H for the treatment of brain tumors. It is anticipated that Alpha1H will be infused intracerebrally for at least one week in humans in order to evaluate its effects on the disease, either alone or in combination with other drugs. To assess the risk of side effects in clinical studies, it is necessary to first determine whether infusions of Alpha1H cause any adverse effects in animal brain tissue.The toxicology study will be performed by Adlego Biomedical; a specialst company that has extensive experience in